Beili Wang1, Feng Li2,3, Luya Cheng2, Yanxia Zhan2, Boting Wu4, Pu Chen1, Junfei Shen1, Wenhao Wu1, Xiaolu Ma1, Jie Zhu1, Baishen Pan1, Wei Guo1, Yunfeng Cheng2,3,5,6. 1. Department of Clinical Laboratory, Zhongshan Hospital Fudan University, Shanghai 200032, PR China. 2. Department of Hematology, Zhongshan Hospital Fudan University, Shanghai 200032, PR China. 3. Department of Hematology, Zhongshan Hospital Qingpu Branch, Fudan Universiy, Shanghai 201700, PR China. 4. Department of Transfusion Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, PR China. 5. Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, PR China. 6. Shanghai Institute of Clinical Bioinformatics, Fudan University Center for Clinical Bioinformatics, Shanghai 200032, PR China.
Abstract
AIM: To explore the prognostic value of the pretreatment platelet (PLT) count in patients undergoing transcatheter arterial chemoembolization (TACE) with hepatocellular carcinoma (HCC). MATERIALS & METHODS: We prospectively analyzed 317 hepatitis B virus-related HCC patients undergoing TACE. Time to progression (TTP) was selected to evaluate the clinical significance of PLT level in HCC patients. RESULTS: PLT was the only parameter showing statistical significance of all the clinical characteristics between two distinct tumor response groups. After ruling out cirrhosis as a potential major confounding factor, the conclusion was further established. Higher pretreatment PLT level, portal vessel invasion and higher stratification of α-fetoprotein level were independently associated with longer TTP. The prognostic score model combining the three risk factors revealed that higher risk scores might mean shorter TTP. CONCLUSION: The pretreatment PLT level is a potentially useful biomarker to predict the prognostic outcomes in HCC patients undergoing TACE and deserves to be further explored in subsequent works.
AIM: To explore the prognostic value of the pretreatment platelet (PLT) count in patients undergoing transcatheter arterial chemoembolization (TACE) with hepatocellular carcinoma (HCC). MATERIALS & METHODS: We prospectively analyzed 317 hepatitis B virus-related HCC patients undergoing TACE. Time to progression (TTP) was selected to evaluate the clinical significance of PLT level in HCC patients. RESULTS: PLT was the only parameter showing statistical significance of all the clinical characteristics between two distinct tumor response groups. After ruling out cirrhosis as a potential major confounding factor, the conclusion was further established. Higher pretreatment PLT level, portal vessel invasion and higher stratification of α-fetoprotein level were independently associated with longer TTP. The prognostic score model combining the three risk factors revealed that higher risk scores might mean shorter TTP. CONCLUSION: The pretreatment PLT level is a potentially useful biomarker to predict the prognostic outcomes in HCC patients undergoing TACE and deserves to be further explored in subsequent works.
Entities:
Keywords:
hepatocellular carcinoma; platelet count; prognosis; time to progression; transcatheter arterial chemoembolization